{"organizations": [], "uuid": "fcd31cac50a95e5a4c248a50390678254367792a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cellectar-biosciences-gets-granted/brief-cellectar-biosciences-gets-granted-orphan-drug-designation-for-clr-131-to-treat-neuroblastoma-idUSFWN1R10LO", "country": "US", "domain_rank": 408, "title": "BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-19T14:40:00.000+02:00", "replies_count": 0, "uuid": "fcd31cac50a95e5a4c248a50390678254367792a"}, "author": "", "url": "https://www.reuters.com/article/brief-cellectar-biosciences-gets-granted/brief-cellectar-biosciences-gets-granted-orphan-drug-designation-for-clr-131-to-treat-neuroblastoma-idUSFWN1R10LO", "ord_in_thread": 0, "title": "BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "clr", "sentiment": "negative"}, {"name": "treat neuroblastoma", "sentiment": "negative"}, {"name": "treat neuroblastoma reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "cellectar biosciences inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 43 PM / Updated 11 minutes ago BRIEF-Cellectar Biosciences Gets Granted Orphan Drug Designation For CLR 131 To Treat Neuroblastoma Reuters Staff March 19 (Reuters) - Cellectar Biosciences Inc: * CELLECTAR BIOSCIENCES GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT NEUROBLASTOMA * ‍CELLECTAR EXPECTS TO INITIATE THIS STUDY DURING Q2 OF 2018​ Source text for Eikon:  ", "external_links": [], "published": "2018-03-19T14:40:00.000+02:00", "crawled": "2018-03-19T15:00:16.018+02:00", "highlightTitle": ""}